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Abstract
The etiology of Parkinson’s disease (PD) is complex and involves numerous risk factors
as environmental and hereditary. Nevertheless, recent studies have established that
systemic inflammation and neuroinflammation are both present in the prodromal phase
and  sustained  during  the  progression  of  the  disease.  Evidence  suggests  that  the
activation  of  the  peripheral  immune  system  exacerbates  the  brain  inflammatory
response, which may initiate or enhance neurodegenerative processes. Understanding
the  impact  of  chronic  systemic  inflammation  in  the  neuroinflammation  and  the
progression of the disease will provide a broader view of the etiology and pathology of
PD.  In  this  chapter,  we  review  the  role  of  the  chronic  systemic  inflammation  in
neuroinflammation  and  its  effect  on  PD,  considering  cell  types,  molecular,  and
inflammatory mediators that predispose to the development of the disease.
Keywords: Parkinson’s disease, chronic systemic inflammation, neuroinflammation,
microglial activation, pro-inflammatory cytokines
1. Introduction
The contribution of systemic inflammation in the progression of several neurodegenerative
diseases slightly has been studied. Inflammatory processes and activation of microglia are both
important  components  in  the  pathogenesis  of  many neurodegenerative  diseases  such as
Parkinson’s  disease  (PD).  Data  support  that  microglial  age-related  cell  changes  induce
cytotoxicity; this may contribute to the onset of neurodegenerative changes.
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
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Indeed, low levels of chronic inflammation are associated with age-related diseases, includ‐
ing atherosclerosis, cardiovascular diseases, diabetes, and PD [1]. This phenomenon is caused
by a persistent antigenic response and oxidative stress accompanied by reduced ability to
counteract with a variety of stress factors, as well as a progressive increase in the pro-inflam‐
matory state [2].
The etiology of PD is complex and involves numerous risk factors as environmental and
hereditary. Nevertheless, recent studies have established that systemic inflammation and
neuroinflammation are both present in the prodromal phase and sustained during the
progression of the disease. Evidence suggests that the activation of the peripheral immune
system exacerbates the brain inflammatory response, which may initiate or enhance neuro‐
degenerative processes. Understanding the impact of chronic systemic inflammation in the
neuroinflammation and the progression of the disease will provide a broader view of the
etiology and pathology of PD. In this chapter, we discuss the role of the chronic systemic
inflammation in neuroinflammation and its effect on PD, considering cell types, molecular,
and inflammatory mediators that predispose to the development of the disease.
2. Neuroinflammation
A few decades ago the central nervous system (CNS) was considered an immunologically
privileged site, a feature that has been attributed mainly to the presence of the blood-brain
barrier (BBB), the low expression of major histocompatibility complex class II (MHCII), and
the lack of brain lymphatic vessels [3].
Under systemic or endogenous pathological conditions, brain immune and glial cells start local
inflammatory events, a situation named neuroinflammation, which is a mechanism of host
defense that aims to restore the structure, recover normal functions, and insult neutraliza‐
tion [4].
Several hypotheses have been postulated on the possible causes of neurodegeneration in PD
patients, which include genetic factors, environmental toxins, mitochondrial dysfunction, and
cell death associated with free radicals [4, 5]. However, now research has focused on neuro‐
inflammation as possible neurodegeneration activator in PD as epidemiological data indi‐
cate that is present even during the asymptomatic phase of the disease [6].
The main neuroinflammatory characteristics present in PD are the presence of activated
microglia and reactive astrocytes; participation of the adaptive immune system; increased
immune molecules such as cytokines, chemokines, among others; and increased oxygen and
nitrogen reactive species concentration (ROS/RNS). These features can lead to the impair‐
ment of the BBB [7].
3. The blood-brain barrier
The BBB is a cellular barrier that regulates the environment of the CNS of vertebrates. It
represents the border between CNS capillaries and extracellular fluid of neurons and glial cells,
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and ensures specific brain homeostasis, allowing proper function of neurons [8]. Although the
BBB becomes more permeable during systemic inflammation [9], the total area of the micro‐
vasculature that composes the BBB in the adult human brain is 12–18 m2 [10] and is the primary
interface for the brain-blood exchange.
The primary function of the BBB is to provide a stable microenvironment for neural function.
At first, it provides optimal concentrations of ions for neural communication, due to the
functional combination of channels and transporters specific ions. For example, in mammals,
the plasma concentration of potassium is 4.5 mM; however, in the cerebrospinal fluid (CSF)
and the interstitial fluid, the levels range between 2.5 and 2.9 mM [11, 12]. Also, brain calcium
and magnesium levels, and the pH are actively regulated by the BBB [13–15].
Moreover, although the peripheral nervous system and CNS use the same neurotransmitters,
the BBB impedes the free flow and maintains the concentrations to avoid phenomena such as
excitotoxicity [16, 17]. Similarly, the CSF protein content is lower than that of blood plasma.
High levels of proteins such as albumin, prothrombin, and plasminogen can activate apop‐
totic cascades, therefore, be locally harmful to the nervous tissue [18–20].
The main elements that conform the BBB are endothelial cells, pericytes, astrocytes (specifi‐
cally astrocytic foots), neurons, microglia cells, and the extracellular matrix. The close
interactions between these components form the neurovascular unit [21] (Figure 1).
The endothelial cells of the BBB differ from the rest of the endothelial cells because they present
tight junctions, low vesicular transport, and multiple transporters, restricting and selecting
molecule flow [22]. Transmembrane tight junctions proteins (occludins, claudins 1–20 and
JAMs) seal the intercellular space of endothelial cells and interact intracellularly with scaffold
proteins (ZO-1, ZO-2, and ZO-3), and other cytoskeletal proteins. In adherens junctions,
cadherins stabilize the adhesion between endothelial cells and catenin binds the cadherin to
the cytoskeleton [23].
Through analysis of the microvasculature of the brain, it showed that astrocytic foot forms a
thin film on the outer surface of the endothelium, suggesting that the astroglia is responsible
for the development and specialization of brain endothelial phenotype [16]. An example that
illustrates this point is the transforming growth factor-β (TGF-β) and angiopoietin-1 pro‐
duced by astrocytes, which increases the expression of tight junction proteins and decreases
the permeability of H3-Sucrose [8].
On the other hand, pericytes share the basement membrane with the endothelial cells of
capillaries, venules, and arterioles, stabilizing the blood vessel wall. Also, pericytes present
receptors for catecholamines, angiotensin II, vasoactive intestinal peptide, vasopressin, and
endothelin-1 that prevent pericyte apoptosis rates in coculture of endothelial cells with
astrocytes [22].
Multiple CNS pathologies such as hypoxia, ischemia [24], edema [25], and neurodegenera‐
tive diseases such as Alzheimer’s, PD and multiple sclerosis [26–28] involve some degree of
BBB dysfunction. An increased BBB permeability facilitates entry of macromolecules such as
albumin into the CNS [29] and changes in blood vessels [30] in patients with PD. These changes
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of BBB permeability contribute to neuronal death in MPTP-intoxicated animal models of PD
[31, 32].
Figure 1. Under physiological conditions, astrocytes and neurons modulate the activation of the microglia. Peripheral
immune cells maintain immune surveillance of brain parenchyma and perivascular space, and CD4+ T cell and macro‐
phages could enter across of intact BBB into the CNS. But under systemic inflammation conditions, peripheral immune
cells can penetrate the BBB and contribute to neuroinflammation.
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One of the main evidence that involves BBB changes in patients with PD stems from a study
of positron emission tomography (PET) that showed an increase of the [11C] verapamil capture
in the midbrain of PD patients suggesting a decrease of P-glycoprotein [33]. Also, it has been
proposed that in these individuals developing changes in the BBB permeability, increased
traffic of iron and magnesium, both involved in the PD pathogenesis [34].
There is growing interest in the study of inflammation as a pathogenic mechanism of PD, which
involves BBB properties alterations as shown in several experimental models [35]. These events
facilitate the establishment of neuroinflammatory phenomena (Figure 1). Regardless of
whether these developments are cause or consequence of neuronal death in PD, the atten‐
tion of researchers focuses on identifying new therapeutic targets for alternative therapies in
the treatment of this disease.
4. Brain-immune cells response in Parkinson’s disease
4.1. Microglia: the major surveillance cell in the CNS
Microglial cells are vital in maintaining an immune homeostasis in the CNS; these cells are the
first defenders against infectious agents and injury-related products in the CNS. Similar to
tissue macrophages, microglia survey the brain for pathogens and support CNS homeostasis
and plasticity, by guarding and remodeling synapses [36].
Under physiological conditions, astrocytes and neurons maintain the microglia in a quies‐
cent or non-activated state [37, 38]. Non-activated microglia constitutively expresses low levels
of HLA-DR in the healthy human brain [39] and MHCII in the rodent brain [40]. In this state,
microglia mainly maintain brain homeostasis with astrocytes. Nevertheless, activated
microglia display more molecular markers of an antigen presentation cell such as MHCII,
CD80, CD86, CD40, CD11a, CD54, and CD58 [41, 42]. These properties show the capability for
antigen presentation of this cell and thus its function of immune surveillance of the brain.
Microglia have all the machinery necessary to detect any foreign molecule that accesses the
CNS parenchyma and can rapidly mount a potent inflammatory response. After immune
stimuli, such as a viral infection or brain injury, microglia cells quickly activate [43, 44] and
acquire a compact phenotype. They upregulate several surface receptors such as receptors for
neurotransmitters, cytokines, and chemokines, as well as pattern-recognition receptors [45–
47]. Several TLRs are expressed on the microglial surface, including TLR2, TLR4, and TLR6
[48, 49].
Microglia also respond and propagate inflammatory signals initiated at the periphery, by
activating and producing pro-inflammatory cytokines such as IL-1β, IL-6, and tumor ne‐
crosis factor alpha (TNFα) [50, 51](Figure 2). These cytokines are indispensable for the
induction and maintenance of the CNS inflammatory state. They also promote the release of
secondary inflammatory mediators including prostaglandins and nitric oxide (NO) [52–54].
Also, they facilitate the production of reactive oxygen species (ROS) through the induction or
activation of NADPH and NO release [55, 56]. Though the activation of microglia and the
Is Chronic Systemic Inflammation a Determinant Factor in Developing Parkinson’s Disease?
http://dx.doi.org/10.5772/62955
111
production of cytokines are transient, once the immune insult is resolved, the microglia return
to a surveying state.
Similar to peripheral macrophages, microglial exposure to IFNγ or TNFα, or stimulation by
microbial agents such as LPS, or other TLR-agonistic compounds or pathogen-associated
molecular patterns, would establish in microglia a “classical” macrophagic activation with an
M1 phenotype. These cells are defense-oriented, release pro-inflammatory and cytotoxic
factors. Cytokines, such as IL-4 or IL-13, instead facilitate an “alternative” activation of
macrophages, also known as M2 phenotype [57]. Recent studies proved that brain microglia
display a distinct profile that is not present in microglial cell lines and differ from M1 or M2
polarized microglia, but rather implicate genes associated with nervous system develop‐
ment [58].
During aging or in some pathologies such as Alzheimer’s disease, microglia display a
heterogeneity analogous to systemic tissue-resident populations [59, 60]. These studies
showed that early in disease progression, microglia develop an altered inducible “activated”
state, which functionally differs from steady state microglia. This activation state is further
subdivided into classical M1 and alternative M2 state [61, 62].
More interestingly is that in neurodegenerative diseases, microglia can get overactivated
resulting in reactive microgliosis, and this might induce neurotoxicity, perturbation of the
neuronal network, maladaptive plasticity, and leading to tissue damage [63]. In PD, micro‐
glia can release pro-inflammatory cytokines, such as IFNγ, IL-1β, TNFα, IL-2, and IL-6 [64],
increases the levels of TNFα receptor R1 (p55), bcl-2, soluble Fas, caspase-1 and caspase-3,
which may contribute to the dopaminergic neurons degeneration [65, 66]. In turn, dopami‐
nergic neuronal death may trigger microglial activation through the loss of the neural
inhibitory CD200 signaling, exposure to α-synuclein, through binding of neuron-bound
complement or antibodies, etc. [67, 68].
4.2. Astrocytes
Astrocytes are the most abundant glial cells of neuroectodermal origin that preserve brain
homeostasis and neuronal functions, participate in maintaining and inducing the BBB, as well
as in nervous tissue repair. Also, they significantly regulate the immune response and express
a set of pattern-recognition receptors involved in innate immune response such as TLRs,
mannose receptors, scavenger receptors, and some components of the complement system
[69]. Astrocytes have a strategic location close to other glial cells and blood vessels and form
a connection between the blood vessels and the brain parenchyma. Moreover, astroglia can be
activated by pattern-recognition receptors ligands or exposure to IFNγ; increasing the
expression of the glial fibrillary acidic protein (GFAP), MHCII, costimulatory molecules (CD80,
CD86, CD40), and adhesion molecules [69]. They possess the ability to secrete cytokines such
as IL 12 and chemokines (CCL2, CCL19, CCL20, and CXCL10) that promote changes in BBB
permeability and favor thus an inflammatory-type response TH1 [69–72]. However, its role as
antigen presenting cell is controversial, and it is thought that their participation is secondary
[3].
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Most findings indicate that microglial cells are the main mediators of neuroinflammation in
the PD, but the presence of reactive astrocytes in the substantia nigra of PD patients is a constant
pathological feature [73]. The increased GFAP expression observed suggests not only a
morphological change but also a functional shift in this type of cell [74]. This phenomenon is
consistent with the decreased production of trophic factors as derived neurotrophic factor glia
and ciliary neurotrophic factor, both substances generated by astrocytes under normal
physiological conditions [74, 75], and this reactivity is proportional to damage dopaminergic
neurons [76].
Astrocytes can detect neurons with α-synuclein accumulation (the main component of Lewy
bodies) and can be activated as a measure of neural protection. A recent study showed that
neural α-synuclein is transferred and accumulated in astrocytes and induces activation of
genes associated with the immune response. In these conditions, astrocytes express cyto‐
kines such as IL-1α, IL-1β, IL-6, IL-18, and colony stimulating factor 1, 2, and 3 [6], chemo‐
kines type CC, CXC, and type CX3C [69].
Also, intercellular adhesion molecule 1 (ICAM-1) positive astrocytes are present in the
substantia nigra of PD patients; it is possible that they attract reactive microglia to the site of
injury since microglial cells expressing the LFA-receptor 1 in the same place are found [77].
The action of α-synuclein on astrocytes is thought to occur via receptors, but the identity of
these receptors is currently unknown [5].
5. Peripheral immune cells participation in Parkinson’s disease
5.1. Macrophages and dendritic cells
The phagocytic cells such as macrophages are restricted to the perivascular space, leptome‐
ninges, and choroid plexus. Macrophages constitutively express MHCII, CD11b, and CD45,
which can help distinguish the microglia since it has a low expression of CD45 in the inacti‐
vated state [70]. In the healthy brain, the primary function is immune surveillance, antigen
capture, and presentation locally and in the cervical lymph nodes. In the case of a lesion,
macrophages participate as antigen presenting cells, in phagocytosis and secretion of pro-
inflammatory cytokines (IFNγ, TNFα, IL-12) and chemokines (CCL2, CCL3) favoring
chemotaxis and inflammation [78, 79]. Also, peripheral macrophages and brain microglia can
secrete inflammasome components (caspase-1, IL-1β, and IL-18) that can induce neurotoxici‐
ty [78, 79]. In contrast, macrophages also have a regulatory role since they can produce anti-
inflammatory and neurotrophic factors as nerve growth factor [80].
Dendritic cells (DCs) can be found primarily in the choroid plexus and meninges [81].
However, they have also been identified in regions lacking BBB such as the circumventricu‐
lar organs, in sites of postnatal neurogenesis, in the perivascular space and even forming part
of the glia limitans of the BBB [82, 83]. They are classified into two main groups (lymphoid
and myeloid) and are assorted into several subpopulations due to cell expressing markers. The
main attributed function in the CNS is immune surveillance, antigen capture, and delivery to
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the cervical lymph nodes, and antigen presentation [84]. However, they also have an impor‐
tant role in inflammation by producing cytokines such as IL-23, IL-1β, IL-12, TNFα, and IFNγ
also IL-10 [81].
After recognizing molecules associated with inflammation, damaged tissue, or autoantigens,
the DCs migrate to sites of inflammation and to lymph nodes to activate T cells and thus
connect the innate immune response and the adaptive immune response. There is little
evidence of the involvement of the DCs in the pathogenesis of PD, but they are recruited from
the blood to the brain where they prime T cells and contribute to the neuroinflammation. A
decrease in the number of peripheral DCs, mainly myeloid, associated with the increased
severity of cognitive and motor symptoms of the disease [85]. Additionally, it has been
reported that DCs treated with neuromelanin (the pigment present in dopaminergic neu‐
rons) acquire a mature phenotype, produce IL-6 and TNFα, and can stimulate T cell prolifer‐
ation [86].
5.2. Lymphocytes
Leukocyte trafficking into the CNS is a highly regulated process, which protects the brain from
a generalized inflammatory phenomenon that could significantly compromise the homeosta‐
sis required for neural functions [87, 88].
Interestingly, the cellular immune surveillance in the healthy human brain differs among CNS
regions and the greatest numbers of immune cells are located in brain regions where the tight
junction barrier of the BBB is reduced, such as the circumventricular organs and the ventror‐
ostral areas of the medulla oblongata [89].
In healthy humans, predominantly activated central memory T cells that expressed high levels
of CCR7, CXCR3, and L-selectin are found in the choroid plexus, the subarachnoid space, and
the CSF [90]. Also, P-selectin facilitates migration of T cells into the CSF of mice and healthy
humans. Furthermore, P-selectin, E-selectin, and ICAM-1 have been detected in vessels of the
choroid plexus and subarachnoid space in humans [91].
Under physiological conditions, the immune surveillance in the perivascular space, with the
participation of T cells that cross the vessel wall of postcapillary venules, however, progress
towards the brain parenchyma dependent antigen presentation by perivascular macrophag‐
es or DCs [3, 83]. Questions have been raised whether the antigen specificity of T cells is a
prerequisite for easy transit to the CNS. Still, several studies have transferred reactive T cells
against neural antigens or irrelevant antigens to animals, and both types infiltrate the
perivascular space similarly, though antigen specificity is required for final access to the
brain [87, 92].
Given the evidence of the role of T cells in the maintenance of brain homeostasis, these could
be implicated in the initiation and progression of PD. In this regard, PD patients and animal
models of PD present infiltrating T CD4+ and CD8+ cells in the substantia nigra [93, 94] and
decreased blood naive T lymphocytes [64, 95, 96]. Similarly, patients with PD have a cytotox‐
ic response by T cell due to a change in the proportion of markers CD4:CD8 and the increase
in the secreted IFNγ production versus IL-4 by lymphocytes [95, 97].
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Other changes in peripheral blood lymphocytes of patients with PD have been reported, and
lymphocytes from patients with PD have a higher incidence of micronuclei, DNA breaks, and
oxidized purine bases [98]. Interestingly, levodopa treatment appears to reduce DNA damage
in lymphocytes of these patients [99]. Furthermore, apoptotic markers, caspase-3, and the
activity of Cu/Zn superoxide dismutase are increased in lymphocytes from patients with PD
[100]. The increased levels of apoptosis and DNA damage could be indicative of a fundamen‐
tal process pathogenic that involves oxidative stress, specific immune responses, and/or
intrinsic factors such as genetic.
B cells are antibody-secreting cells of the immune system and the key mediators of the humoral
response [101].
Patients with PD display antibodies against α-synuclein as well as against other epitopes from
the CNS [102, 103]. Nevertheless, the presence of antibody producing B cells in the CNS of PD
patients has not been reported [93, 94] despite the decrease in peripheral B lymphocytes [95,
96]. Deletion of the B cell counts in autoimmune diseases and other inflammatory diseases are
secondary to reduced circulating memory B cells, which can be related to an inflammatory
process or cellular activation [104, 105]. These events can occur in the substantia nigra in PD
and that could explain the B cell decrease in the periphery of these patients.
6. Main cytokines and chemokines involved
Cytokines are proteins with pleiotropic actions that mediate many of the functions of im‐
mune cells and are mainly secreted by immune cells but also parenchyma brain cells. Multiple
cytokines (IFNγ TNFα, IL-1β, IL-6, IL-18, IL-4, IL-10, IL-11, IL-13, TGF-β, IL-17, and IL-23) are
found in the CNS, even under physiological conditions [106, 107].
It has been shown that PD patients present increased plasma cytokines such as IL-2, IL-4, IL-6,
IL-10, TNFα, and IFNγ [108, 109]. Also, high levels of these cytokines and other inflamma‐
tion markers are related to the risk of idiopathic PD [110]. Postmortem studies have found
over-expression of pro-inflammatory cytokines (IL-1β TGF-α, IFNγ, and IL-6) in CSF and
nigrostriatal regions of PD patients [111, 112]. Also, proteins of the complement system are
found associated with extra-neuronal Lewy bodies [113]. As mentioned earlier, genetic factors
are strongly related to the PD, polymorphisms of IL-8, IL-17, and IL-10 genes are associated
with the risk of developing sporadic PD [114]. The findings suggest that activation of the
immune response occurs in association with or in response to the Lewy bodies’ formation [115].
Chemokines, which play important roles in neuroinflammation as mediators of leukocyte
infiltration, are among the most important inflammatory factors [116]. They are proteins
mediating the response and traffic of leukocytes and are classified into four subfamilies: C,
CC, CXC, and CX 3. In the CNS, chemokines are mainly produced by glial cells and its primary
function is chemotaxis or attraction of leukocytes to the damaged area promoting inflamma‐
tion. The main CNS chemokines are monocyte (CCL2, CCL3, CCL4), lymphocyte (CCL5)
chemoattractant, IFNγ-induced (CXCL10), among others [117, 118].
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A prominent member of the chemokine family is CXCL12 or stromal-derived factor-1 alpha
(SDF-1a) and its receptor CXCR4. Both CXCL12 and CXCR4 are constitutively expressed and
modulate a variety of CNS functions, including neurogenesis [119], axonal growth [120],
pain [121], and neurotransmission [122]. High expression of CXCL12 and CXCR4 is present in
the rodent substantia nigra [123] and modulate dopamine transmission [124]. In the human
substantia nigra, CXCR4 immunoreactivity was high in dopaminergic neurons [125].
Regarding PD, patients show elevated levels of CCL5 in the serum, and its concentrations are
higher in patients with greater severity of symptoms [109]. Interestingly, the substantia nigra
of patients with PD exhibited higher expression of CXCR4 and CXCL12 than control sub‐
jects despite the loss of dopaminergic neurons. This effect was accompanied by an increase in
activated microglia [125].
We can finally say that levels of CCL2 expressed by peripheral blood mononuclear cells were
higher in PD patients than in healthy control. CCL2 levels are also correlated with the Unified
Parkinson’s Disease Rating Scale (UPDRS)-III and Hoehn-Yahr stage [109]. Moreover, a recent
study showed that elevated CCL2 CSF levels were associated with more severe symptoms of
depression in PD patients [126].
7. Contribution of systemic and neuroinflammation in Parkinson’s disease
development
The contribution of systemic inflammation in the progression of several neurodegenerative
diseases has been slightly studied. Inflammatory processes and activation of microglia are both
important components in the pathogenesis of many neurodegenerative disorders such as PD;
epidemiological evidence suggests an association between neuroinflammation and PD [35].
The PD, such as other neurodegenerative diseases, is associated with aging, which is related
to increased formation of ROS predisposing the cell to damage and dysfunction. The evi‐
dence points to a relationship between oxidative stress and inflammation in the excessive
production of free radicals that can induce an inflammatory response [1].
7.1. Cytokines contribution
Several studies have reported increases and decreases in the levels of pro-inflammatory
cytokines and neurotrophins in the brain of PD patients [127], suggesting that neurons could
be more susceptible to neuroinflammation and apoptosis, thus contributing to the pathogen‐
esis of PD.
High levels of TNFα, IL-1β, IL-2, IL-4, IL-6, TGF-α, TGF-β1, and β2 have been detected in the
brain parenchyma or CSF of PD patients [94, 128–130]. In accordance, the activated micro‐
glia can be a source of pro-inflammatory cytokines since in the substantia nigra of PD patients
microglial overactivity was observed [46, 131–135]. An additional source of pro-inflammato‐
ry cytokines is the presence of CD8+ T lymphocytes in the vicinity of degenerating neurons
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[94]. Cytotoxic T CD8+ is directly neurotoxic in autoimmune and aging-associated neurode‐
generative disorders of the CNS [136]. This observation suggests that an infiltration of immune
cells through the BBB may also contribute to the pathophysiology of PD. In this regard,
peripheral blood mononuclear cells from PD patients express significantly higher levels of
CCL2, CCL3, CCL5, IL-8, IFNγ, IL-1β, and TNFα after LPS stimulation than in healthy
subjects [109].
It is possible that as well local as peripheral pro-inflammatory cytokines contribute to the loss
of the BBB integrity facilitating the entrance of peripheral immune cells into the CNS. The role
of peripheral immune cell traffic into the brain and its relevance in PD have not been exten‐
sively explored, but some studies show the implication of CD4+ T cells since mice lacking CD4+
cells are protected from MPTP-induced nigrostriatal neurons degeneration [93].
7.2. Microglia priming
Figure 2. The relationship between peripheral inflammation and neuronal loss in PD. Neurodegenerative diseases
present microglial activation as the chief hallmark, which can change its morphology from resting towards an activat‐
ed or primed shape. The intermediate stage, “primed microglia,” describes the atypical microglial stage, which pre‐
cedes a further neurotoxic microglial activation as a consequence of a secondary pro-inflammatory stimulus. This
intermediate stage could be a consequence of pro-inflammatory stimuli evoked by obesity, aged, or a systemic infec‐
tion. Activated microglia releases pro-inflammatory cytokines which can act on dopaminergic neuronal integrity.
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Primed microglia is the state when microglia respond to a secondary inflammatory stimulus
with an exaggerated inflammatory response; this form of microglia contributes significantly
to neuroinflammation and death of dopaminergic neurons (Figure 2). A recent study report‐
ed that a single paraquat exposure induced microglia activation with induction of the NADPH
oxidase. If this activation was blocked with the anti-inflammatory drug minocycline, subse‐
quent exposures to the paraquat failed to cause oxidative stress and neurodegeneration [137].
Also, systemic LPS administration resulted in rapid brain TNFα increase that remained
elevated for 10 months activating microglia and secondarily increasing the expression of brain
pro-inflammatory factors (i.e., TNFα, CCL2, IL-1β, and NF-κB). Further, tyrosine hydroxy‐
lase-immunoreactive neurons in the substantia nigra are reduced after LPS exposure and these
data demonstrate that peripheral inflammation can activate brain microglia to produce
chronically elevated pro-inflammatory factors, favoring a progressive loss of dopaminergic
neurons of the substantia nigra [138].
Other works showed that priming of microglia with LPS predisposes susceptibility of
dopaminergic neurons to neural toxins such as paraquat and 6-hydroxydopamine (6-OHDA),
favoring the secretion of IL-1β, triggering the loss of these neurons, and suggesting a close
relationship between neurodegeneration and inflammation [139, 140].
Therefore, microglial priming may in part regulate microglial phenotype and shift micro‐
glial activities from neuroprotective to neurotoxic (i.e., from trophic factor synthesis to
production of ROS/RNS, among others), leading to hasten the death of vulnerable neuronal
populations [141, 142].
Increased susceptibility to inflammation-induced nigral degeneration was shown in Parkin-
deficient mice treated chronically with intraperitoneal low-dose of LPS, mice developed
neuroinflammation and selective loss of dopaminergic neurons of substantia nigra [143].
Also, the systemic co-administration in mice of LPS and α-synuclein significantly increased
IL-1β, IL-6, and TGF-β mRNA when compared with animals treated with α-synuclein alone.
These observations suggest that any activator of the innate immune system, such as a
peripheral pathogen, will alter the pathogenesis of PD by generating a transient pro-inflam‐
matory environment that is likely to accelerate neurodegeneration [144].
7.3. What role plays aging?
Many age-related changes affect the CNS, contributing to both oxidative stress and inflam‐
mation deterioration of certain functions; thus, these processes singly and collectively affect
neuronal viability and increase vulnerability. Data support that microglial age-related cell
changes induce cytotoxicity, and this may provide to the onset of neurodegenerative changes.
It has been observed that basal mRNA expression of markers of activated microglia such as
CD11b and Iba-1 was higher in the aged hippocampus when compared to the adult [145].
Moreover, aging increased macrophage infiltration in the brain, with increased expression of
IFNγ and the TLR4 agonists, high-mobility group protein B1 (HMGB1) [146].
Microglia seem to be activated at baseline in the elderly [94]. Furthermore, microglial cells
obtained from aged mice developed lipofuscin granules, reduced the complexity of process‐
Challenges in Parkinson's Disease118
es ramification, and increased mRNA levels of several pro-inflammatory cytokines (TNFα,
IL-1β, and IL-6) as well as several anti-inflammatory cytokines (IL-10 and TGF-β) when
compared with young mice. Also, when a pro-inflammatory stimulus is performed by a single
dose of LPS, expression of TNFα IL-1β, IL-6, and IL-10 is increased but not of TGF-β [147].
These elevated cytokine levels may modify the microglial function and predispose micro‐
glial cells to become cytotoxic and cause neurodegenerative changes [148].
Upon aging, there are hormonal, immunological, and fatty changes that lead to a chronic
inflammatory state [149]. These changes promote cognitive, cardiac, neuronal deterioration,
and the occurrence of vascular events. However, if pro-inflammatory molecules outgrow anti-
inflammatory responses, an imbalance occurs establishing a chronic inflammatory state [1,
150]. Therefore, this apparent imbalance in innate immune responses and pro-inflammatory
molecules present in aging leads to a low-grade chronic inflammatory condition commonly
present in elderly [150].
In this context, obesity results in a chronic inflammatory environment and may be associat‐
ed with increased systemic oxidative stress. Levels of pro-inflammatory cytokines, such as IL-6
and TNFα, are significantly higher in obese subjects than in lean subjects [151, 152]. It becomes
relevant since mortality was higher in obese animals than in control mice in the MPTP mice
model, suggesting that obesity may increase the vulnerability of dopaminergic neurons to
MPTP via increased levels of ROS and pro-inflammatory cytokines [153].
8. Conclusions
In recent decades, has deepened in the study of neuroinflammation as an important factor in
etiology and development of PD, finding enough evidence to affirm that neuroinflammation
is an adverse process for neuronal survival and function of individuals with this disease.
The immune system continues to undergo changes throughout life. The evidence shows that
chronic inflammatory conditions caused by infectious, degenerative diseases or conditions
such as aging and obesity, contribute to the establishment of neuroinflammation and the
development of neurodegenerative phenomena, mainly in microglia rich brain regions, as the
substantia nigra.
The full impact of systemic inflammation on brain immune changes remain poorly under‐
stood. The existence of a close association between systemic inflammation and neuroinflam‐
mation is evident in the progression of neurodegenerative disorders.
The cross-talk between immune cells and nervous system, especially microglia, is of particu‐
lar importance in damage processes that precede PD. Based on current evidence, blocking
microglia-derived inflammatory mediators or modulating the peripheral immune cells may
be potentially useful therapies. However, it is important to explore in parallel the cellular,
molecular and functional changes occurring during systemic inflammation, and thus, it may
be possible to analyze the implications of this inflammation in recent Parkinson development.
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Although research has been extensive, it is necessary to deepen this area of knowledge,
especially in countries with a high number of individuals with obesity or metabolic syn‐
drome, to assess and reduce the risks of increasing prevalence of PD and other neurodege‐
nerative diseases.
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